Zenas BioPharma's Phase 3 INDIGO trial for obexelimab demonstrated a 56% reduction in disease flare-ups and better safety compared to placebo in treating IgG4-related disease. With $718.5 million in cash and milestone funding, the company is well-funded through mid-2029 to prepare for product launch and expand into lupus and multiple sclerosis treatments. The company's valuation is high but justified by its late-stage assets, upcoming FDA review, and potential for broader autoimmune applications, with key catalysts expected in late 2026.
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Figure Technology Solutions, a leader in blockchain-based capital markets, announced it will release its second quarter 2026 financial results on August 13, 2026, before the market opens. The company will hold a conference call at 8:30 a.m. Eastern T...
Ecovyst Inc., a leading provider of sulfuric acid products and services, announced a conference call on August 5, 2026, to discuss its second quarter financial results. Investors can access the call via phone or webcast. The company specializes in su...
